Lilly CEO: Monoclonal Antibody Companies Should Share Coronavirus Manufacturing Capacity
David Ricks says a consortium of companies will be needed to ensure enough doses of the successful candidates are available.
You may also be interested in...
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.
Companies are shielded from antitrust concerns by Justice Department as they jointly prepare to manufacture whichever monoclonal-antibody-based coronavirus therapies emerge from development.